Current Overview of the Diabetic Macular Edema

1. Aiello, L., Gardner, T., King, G. et al.: Diabetic Retinopathy. Diabetes Care 1998; 21: 143–156.

2. Arevalo, F.: Retina Angiography and Optical Coherence Tomography. Springer Science USA 2009; 471.

3. Aveleira, C., Lin, C., Abcouwer, S., Ambrosio, A., Antonetti, D.: TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability. Diabetes, 2010; 59: 2872–82.

4. Bandello, F.: Seminars in Ophthalmology, 2001, vol. 16, No1. pp. 2–41.

5. Brenick, G.: Diabetic maculopathy: a critical review highlighting diffuse macular edema. Ophthalmology, 1983; 1301–1317.

6. Bresnick, G.: Diabetic macular edema: e review. Ophthalmology, 1986; 93: 989–997.

7. Dodson, P.: Diabetic Retinopathy. Oxford University Press 2008; 17.2

8. Dodson, P.: Managing Diabetic retinopathy. nowPharma LTD. 2011; 84.

9. Duh, E.: Diabetic Retinopathy. Human press 2008; 494.

10. Diabetic retinopathy Clinical Research Network. A randomized Trial comparing intravitreal triamcinolone acetionicde and focal/grid photocoagulation for diabetic maculoar edema. Ophthalmology, 2008; 115: 1447–1459.

11. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 2010; 117(6):1064–1077.

12. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329: 977–86.

13. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report No.1 Arch Ophthalmol.1985; 103: 1796–1806.

14. Easty, L., Sparrow, J.: Oxford textbook of ophthalmology. New York: Oxford University Press 1999; 1308.

15. Gastinger, M, Kunselman, A, Conboy, E. et al.: Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2 Akita diabetic mice. Incest Ophthalmol Vis Sci, 2008; 49: 2635–42.

16. Gowda, K, Zinnanti, W, LaNoue, K.: The influence of diabetes on glutamate metabolism in retinas. J Neurochem, 2011; 117: 309–20.

17. Hanas, R., John, G.: On behalf of the International HBA1c Consensus Committee: 2010 Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C: Ann Clin Biochem, July 1, 2010; 47(4): 290–291.

18. Hotamisligil, S.: Inflammation and metabolic disorders. Nature, 2006; 444: 860–7.

19. Chew E., Klein M., Ferris F., et al.: Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. Arch Ophthalmol, 1996; 114: 1079–84.

20. Joussen, A., Poulaki, V., Mitsiades, N., et al.: Nonsteroidal anti-inflammatory drugs present early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16: 438–40.

21. Joussen, A, Poulaki, V, Qin, W, et al.: Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthese expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol, 2002; 160: 501–9.

22. Keech, A.C., Mitchell, P., Summanen, P., et al.: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007; 370: 1687–97.

23. Klein, R., Klein, B., Moss, S., Mets, D.: Is blood pressure a predictor of the incidence or progression of diabetic retinopathy? Arch Int Med, 1989; 149: 2427 – 2432.

24. Klein, R., Klein, B., Moss, E., Devis, M., De Mets, L.: Glycosilated haemoglobin predicts the incidence and progression diabetic retinopathy. JAMA 1988; 260: 2864–71.

25. Kuchyňka, P. a kol.: Oční lékařství. Praha: Grada 2007; 768.

26. Larson, H, Polsen, J.: Intraocular tension and blood sugar fluctuation in diabetes. Acta Ophthalmol, 1962; 40: 580–9.

27. Massin, P., Bandello, F., Garweg, J., et al.: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, doublemasked, multicenter phase II study. Diabetes Care, 2010.

28. Mitchell, P., Bandello, F., Schmidt-Erfurth, U. et al.: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macula edema. Ophthalmology, 2011; 118: 615–625.

29. Murphy, R.: Management of diabetic retinopathy. Am Fam Physician, 1995; 51, 4: 785–796.

30. Pelikánová, T., Bartoš, V.: Praktická diabetologie 5. vyd. Maxdorf 2011; 738.

31. Pickup, J, Williams, G.: Textbook of diabetes, 2nd ed. volume two. Oxford: Blackwell Science Ltd. 1997; n.p.

32. Ryan, J.: Retina. 3rd ed. volume two. St. Louise : Mosby, Inc. 2001; 1847.

33. Scanlon, P., Aldington, S., Wilkinson, Ch. et al.: Practical Manual of Diabetic Retinopathy Management. Wiley-Blackwel 2009; 232.

34. The ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: design and methods. Am J Cardiol, 2007; 99: Suppl: 21-33.

35. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993; 329: 977–86.

36. Škrha, J. et al.: Diabetologie. Praha: Galén 2009; 417.

37. UK Prospective Diabetes Study (UKDPS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKDPS 38. B M J 1998; 317: 703–13.

38. VanGuilder, H., Brucklacher, A., Patel, K.  et al.: Diabetes downregulates presynaptic proteins and reduces basal synapsin1 phosphorylation in rat retina. Eur J Neurosci 2008; 28: 1–11.

39. Wang, J., Xu, X., Elliott, M., Zhu, M., LeYZ.: Müller cell-derived VEGF is Essentials for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010; 59:2297-305.

40. Williams, R, Herman, W, Kinmonth, AL, Wareham, NJ.: The Evidence Base for Diabetes Care. John Wiley & sons, LTD Englad, 2002. pp. 784.